OVERVIEW
This webinar utilizes a team approach to explore challenges and provide best practices for conducting clinical and translational research during the COVID pandemic. A multidisciplinary faculty composed of physician researchers, a nurse clinical coordinator, a patient advocate and a pharmaceutical company representative will discuss the following topics: review and implementation of federal and international COVID guidelines, best practices for keeping clinical trials accessible to patients and labs open, best practices for study coordination and team wellness, and the effect of COVID on patients. Afterwards there will be time for discussion and Q & A.

Disclosures
Faculty and Planners
Antoinette Wozniak, MD, FACP, FASCO discloses she is a consultant for Regeneron, Epizyme, Lilly, Bristol Meyer Squibb, Novocure and GlaxoSmithKline and on a DSMB for Odonate, HUYA and BeyondSpring.

Jyoti Patel, MD, FASCO discloses she is a consultant for AbbVie, AstraZeneca and Takeda.

Buerkley Rose, MSN, RN, HPE has no financial relationships to disclose.

Amy C. Moore, PhD discloses she is on an advisory board for Guardant and receives grant support from Genentech and Bristol Meyers Squibb.

Christian Rolfo, MD, PhD, MBA, Dr.hc. discloses he is on an advisory board for Mylan and Oncompass, receives honorarium from MSD and GuardantHealth and has research grants from OncoDNA, Biomark and GuardantHealth.

M. Catherine Pietanza, MD discloses she has ownership/stock interest in Merck and Co, Inc. and is also an employee of Merck and Co, Inc.

Joachim Aerts, MD, PhD discloses he is on an advisory board for BMS, Roche, Eli-Lilly, Boehringer Ingelheim, Takeda, MSD, Astra Zeneca and Amphera. He also discloses he has ownership or stock interest in Amphera and is a royalty or intellectual property holder for Allogenic tumor-cell Lysate, Combination immunotherapy in oncology, Biomarker for immuno oncology.

Kirsten Black, PhD, MPH has no financial relationships to disclose.

Aubrey Shoe, MA has no financial relationships to disclose.

All other planners, reviewers and staff reported no relevant financial relationships. All relevant financial relationships have been mitigated.